Sify.com » Topics » Obesity
Obesity News
Report: Fight fat even in toddlers, preschoolers
A food pyramid just for the under-2 set? Contrary to popular belief, children don't usually outgrow their baby fat — and a new report urges steps to help prevent babies, toddlers and preschoolers from getting too pudgy too soon.That's a growing problem: Already, one in five preschoolers — 2- to 5-year-olds — is overweight or obese.Topping the list of proposed changes: better guidelines
A food pyramid just for the under-2 set? Contrary to popular belief, children don't usually outgrow their baby fat — and a new report urges steps to help prevent babies, toddlers and preschoolers from getting too pudgy too soon.That's a growing problem: Already, one in five preschoolers — 2- to 5-year-olds — is overweight or obese.Topping the list of proposed changes: better guidelines
Report: Fight fat even in toddlers, preschoolers
A food pyramid just for the under-2 set? Contrary to popular belief, children don't usually outgrow their baby fat — and a new report urges steps to help prevent babies, toddlers and
How eating junk food destroys brain cells that control weight
A study has found that eating too much of fatty junk food destroys the brain cells that control weight, leading to a vicious circle of obesity.
A study has found that eating too much of fatty junk food destroys the brain cells that control weight, leading to a vicious circle of obesity.
CDC: 1 in 4 high schoolers drink soda every day
A new study shows one in four high school students drink soda every day — a sign fewer teens are downing the sugary drinks.
A new study shows one in four high school students drink soda every day — a sign fewer teens are downing the sugary drinks.
Orexigen puts obesity drug development on hold
The maker of a weight loss drug once seen as a potential blockbuster said it is scrapping its bid for U.S. approval because of "unprecedented" demands by regulators on safety trials.
The maker of a weight loss drug once seen as a potential blockbuster said it is scrapping its bid for U.S. approval because of "unprecedented" demands by regulators on safety trials.
Orexigen puts obesity drug development on hold
Orexigen Therapeutics Inc. says regulators are making "unprecedented" demands about safety trials for its obesity drug candidate Contrave, and says it will put further development on hold until it
© Copyright Sify Technologies Ltd, 1998-2011. All rights reserved. India News Portal, Sify.com hosted at SifyHosting India's first Level 3 Internet Data Centre.
Site optimized for Internet Explorer 5.5 and above.
See Disclaimer |Privacy Policy &Parental Guidance on pornography |careers@sify |About Us |Feedback |Advertise
Site optimized for Internet Explorer 5.5 and above.
See Disclaimer |Privacy Policy &Parental Guidance on pornography |careers@sify |About Us |Feedback |Advertise